Loading...

DYN DYNE THERAPEUTICS INC Earnings Reports 8-K Filing

DYN

DYN

DYNE THERAPEUTICS INC

(DYN)

2025 8-K

Show Summary

Show Summary

Accelerated Approval Pathway

Financial Statements

Management Change

Financial Results

Financial Update

Financial Results

Leadership Changes

Financial Results

Annual Meeting of Stockholders

Public Offering

Clinical Trial Results

Financial Results Announcement

Appointment of President an...

Financial Results Announcement

Public Offering

Suspension of Prospectus

Clinical Trial Results

Financial Results Announcement

Financial Results Announcement

Departure of Directors

Financial Results Announcement

Regulation FD Disclosure

Financial Results Announcement

External Links:

Dyne Therapeutics expects to report approximately $642 million in cash and marketable securities as of December 31, 2024, and announced new clinical data from its ongoing trials for treatments of myotonic dystrophy and Duchenne muscular dystrophy.

AI Assistant

DYNE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.